Paul H. Berg
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Schizophrenia research and treatment, Cardiac electrophysiology and arrhythmias, Bipolar Disorder and Treatment, Electroconvulsive Therapy Studies, Migraine and Headache Studies
Most-Cited Works
- → Anti–TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy(2016)267 cited
- → Lasmiditan is an effective acute treatment for migraine(2018)265 cited
- → Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation(2023)167 cited
- → Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia(2005)154 cited
- → Analysis of the QTc Interval During Olanzapine Treatment of Patients With Schizophrenia and Related Psychosis(2001)120 cited
- → Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials(2019)88 cited
- → Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease(2019)74 cited
- → The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome(1999)71 cited
- → Olanzapineversushaloperidol in the treatment of schizoaffective disorder(1999)69 cited
- → Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls(2020)61 cited